CClinicalTrials.gg
WithdrawnNCT01221740Updated Jan 12, 2017

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

A Phase 3 interventional study of Savella in Back Pain, sponsored by Brigham and Women's Hospital. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Brigham and Women's Hospital · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Company decided to discontinue
Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

  1. To show that patients with greater pain sensitivity will show greater improvement in their symptoms (self-reported pain intensity, mood, sleep, and quality of life) than those with lower pain sensitivity, based on QST, after taking milnacipran.
  2. To compare outcome differences (pain intensity, mood, activity interference, sleep, and side effects) with those patients who are either taking or not taking opioids for their pain 10 weeks after being prescribed milnacipran.
  3. To show that patients who are older, male, with more medical comorbidities, greater disability, and longer pain duration will report less improvement (pain, mood, sleep, health-related quality of life) and treatment satisfaction while taking milnacipran compared with others without such characteristics.
Read the detailed description

Chronic pain is a costly syndrome that influences every aspect of a patient's life. Significant interference with sleep, employment, social functioning, and daily activities is common. Chronic pain patients frequently report depression, anxiety, irritability, sexual dysfunction, and decreased energy. Family roles are altered, and worries abound about financial limitations and future consequences of a restricted lifestyle. Epidemiological studies have independently documented that chronic pain is an immense international problem. Chronic pain symptoms afflict one third of the American population (more than 80 million people). Chronic pain accounts for 21% of emergency room visits and 25% of annual missed work days. When direct and indirect costs are considered, chronic pain imposes a greater economic burden than any other disease, with annual estimates up to $100 billion.

Patients will complete a number of questionnaires at baseline and undergo quantitative sensory testing (QST) as well as complete a handheld electronic diary PDA throughout the entire 10 weeks of the study. Patients will be evaluated by a physician and receive a complete history and physical. Radiological studies will be consulted to confirm diagnosis. All subjects who consent to participate in this study will be started on or converted to milnacipran if they are currently taking an SSRI, buproprion, or a TCA. This will be done over a 1 to 2 week period of gradually weaning the antidepressant and escalating milnacipran. All other adjuvant medication will remain constant through the course of the 10-week trial. Efforts will be made to recruit at least 40% of the patients (N= 24) who are not taking opioids for pain.

At the end of the study, all patients will repeat the baseline questionnaires listed above except the demographic questionnaire. They will also be asked to complete the Treatment Helpfulness Questionnaire. We will compare secondary outcome differences (treatment satisfaction and helpfulness) between patients either on or off of opioids.

02

Conditions studied

  • Back Pain

Browse trials for

Keywords

  • To show that patients with greater pain sensitivity
  • will show greater improvement in their symptoms
  • (self-reported pain intensity, mood, sleep, and
  • quality of life) than those with lower pain
  • sensitivity, based on QST, after taking milnacipran.
  • To compare outcome differences
  • (pain intensity, mood, activity interference,
  • sleep, and side effects) with those patients
  • who are either taking or not taking opioids for
  • their pain 10 weeks after being prescribed milnacipran.
  • To show that patients who are older, male,
  • with more medical comorbidities, greater disability,
  • and longer pain duration will report less improvement
  • (pain, mood, sleep, health-related quality of life)
  • and treatment satisfaction while taking milnacipran
  • compared with others without such characteristics.
  • identify patients back or neck pain
  • greater 6 months
  • QST
  • 10 weeks
  • milnacipran
  • pain intensity
  • mood
  • activity
  • interference
  • sleep
  • side effects
  • age
  • gender
  • medical comorbidities
  • pain diagnosis
  • pain duration
  • disability status
03

In context

Back Pain

2,373 studies on the registry are indexed under Back Pain; 284 are open to participants now.

Browse Back Pain studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years or older
  • Primary diagnosis of spinal pain for at least 6 months' duration
  • Average pain intensity score of 4 or greater

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of cancer or malignant disease
  • Acute bone disease
  • History of DSM-IV psychotic disorder
  • Pregnancy
  • Any illness judged by the PI to interfere with treatment
  • Any acute condition requiring surgery
  • Currently taking SNRI or MAOI
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Milnacipran

    The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period. 12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8

    Drug: Savella

Interventions

  • DrugSavella

    The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks. 12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8

    Also known as: HCL (Savella), Milnacipran

06

What researchers measure

Primary outcomes

  1. Decreased Back Pain

    Decreased Back Pain on the Brief Pain Inventory Scale.

    Time frame: Over the course of 10 weeks

07

Study locations

1 site
  • Brigham and Women's Hospital Pain Trials Center
    Chestnut Hill, Massachusetts 02467, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01221740
Lead sponsor
Brigham and Women's Hospital
Collaborators
Forest Laboratories
Responsible party
Robert N. Jamison, PhD (Robert Jamison, PhD, Brigham and Women's Hospital) — Principal investigator
First posted
Oct 15, 2010
Start date
Aug 2010
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Jan 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion